Quoin Pharmaceuticals Secures $104.5M in Private Placement

Quoin Pharmaceuticals ( (QNRX) ) has shared an update.

On October 10, 2025, Quoin Pharmaceuticals announced a private placement agreement with institutional investors to raise up to $104.5 million, including an initial $16.6 million. The funds will support corporate purposes and the development of QRX003 for Netherton Syndrome. The placement closed on October 14, 2025, and is expected to fund the company into 2027, enhancing its market position in rare disease therapeutics.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Its innovative pipeline includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, and Scleroderma, among others.

Average Trading Volume: 285,181

Technical Sentiment Signal: Sell

Current Market Cap: $8.74M

For an in-depth examination of QNRX stock, go to TipRanks’ Overview page.